Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT00522938 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Very poor recruitment of patients to the study

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: CHR-2797 (tosedostat)
DRUG: erlotinib

Sponsor

Chroma Therapeutics